Founder & CEO
In addition to his roles as Founder and CEO of B. More, Ceruvia Lifesciences and Freedom to Operate, Carey is the chair of the advisory board to NYU’s Center for Psychedelic Medicine, board member and president of the Heffter Research Institute.
Director, NYU Langone Center for Psychedelic Medicine
Considered one of the world’s foremost experts in addiction research, Dr. Bogneschutz has extensive experience in clinical research involving both pharmacologic and psychosocial treatments for substance use disorders and other mental health conditions. His current work is aimed at understanding the health-related effects of psychedelics and related compounds, including their therapeutic effects, safety, and mechanisms of action. Dr. Bogenschutz currently serves as the National Institute on Drug Abuse clinical trials network administrator.
A primary focus of Dr. Bogenschutz’s research is the use of psilocybin to treat alcohol use disorder. In August 2022, Dr. Bogenschutz published the first placebo-controlled trial exploring the treatment of alcohol use disorder (AUD) with psilocybin. The results, published in JAMA psychiatry reported 83% average reduction in heavy drinking among those receiving psilocybin combined with psychotherapy, a dramatic improvement over currently available treatments.